Nkarta Inc Total Assets
Nkarta Inc total assets. Based on the latest financial reports, Nkarta Inc (NKTX) holds total assets worth $337.64 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NKTX market cap for the company's overall valuation and market capitalisation.
Total Assets of Nkarta Inc (2018–2025)
Total assets of Nkarta Inc from 2018 to 2025. This chart illustrates how Nkarta Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Nkarta Inc for real-time trading data and today's change.
Nkarta Inc - Asset Composition Analysis
Nkarta Inc Total Assets Breakdown (December 2025)
Nkarta Inc total assets breakdown as of December 2025. Nkarta Inc's total assets of $337.64 Million consist of 69.9% current assets and 30.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.8% |
| Accounts Receivable | $2.00 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Nkarta Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Nkarta Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nkarta Inc's current assets represent 69.9% of total assets in 2025, a decrease from 85.7% in 2018.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2025, down from 81.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Nkarta Inc Competitors by Total Assets
Key competitors of Nkarta Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Nkarta Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.98 | 15.67 | 21.96 |
| Quick Ratio | 7.98 | 15.67 | 21.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $164.48 Million | $277.64 Million | $252.59 Million |
Nkarta Inc - Advanced Valuation Insights
This section examines the relationship between Nkarta Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -19.4% |
| Total Assets | $404.21 Million |
| Market Capitalization | $109.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nkarta Inc's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Nkarta Inc's assets decreased by 19.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nkarta Inc (2018–2025)
The table below shows the annual total assets of Nkarta Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $404.21 Million | -19.35% |
| 2024-12-31 | $501.20 Million | +32.28% |
| 2023-12-31 | $378.88 Million | -19.89% |
| 2022-12-31 | $472.94 Million | +72.67% |
| 2021-12-31 | $273.90 Million | -18.88% |
| 2020-12-31 | $337.65 Million | +597.45% |
| 2019-12-31 | $48.41 Million | +404.01% |
| 2018-12-31 | $9.61 Million | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more